A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)

Daniel R. Greenwald; Hailun Li; Selina M. Luger; Ronald S. Go; David King; Taral Patel; Randy D. Gascoyne; Jill Kolesar; Brad S. Kahl; Sandra Horning

doi:10.1186/1756-8722-6-46

A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)

Daniel R. Greenwald, Hailun Li, Selina M. Luger, Ronald S. Go, David King, Taral Patel, Randy D. Gascoyne, Jill Kolesar, Brad S. Kahl, Sandra Horning

Hematology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

Original language	English (US)
Article number	46
Journal	Journal of Hematology and Oncology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1186/1756-8722-6-46
State	Published - 2013

Keywords

Diffuse large B cell lymphoma
MAP kinase signaling
NHL
Sorafenib

ASJC Scopus subject areas

Molecular Biology
Hematology
Oncology
Cancer Research

Access to Document

10.1186/1756-8722-6-46

Cite this

Greenwald, D. R., Li, H., Luger, S. M., Go, R. S., King, D., Patel, T., Gascoyne, R. D., Kolesar, J., Kahl, B. S., & Horning, S. (2013). A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404). Journal of Hematology and Oncology, 6(1), Article 46. https://doi.org/10.1186/1756-8722-6-46

@article{e1b137f039c94616b685304327264fa8,

title = "A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)",

abstract = "Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.",

keywords = "Diffuse large B cell lymphoma, MAP kinase signaling, NHL, Sorafenib",

author = "Greenwald, {Daniel R.} and Hailun Li and Luger, {Selina M.} and Go, {Ronald S.} and David King and Taral Patel and Gascoyne, {Randy D.} and Jill Kolesar and Kahl, {Brad S.} and Sandra Horning",

note = "Funding Information: We would like to thank Dr. Ranjana Advani for her help in study implementation and review of the manuscript. This investigation was supported by Grant CA-23318, awarded by the National Cancer Institute, DHHS. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA15488, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.",

year = "2013",

doi = "10.1186/1756-8722-6-46",

language = "English (US)",

volume = "6",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma

T2 - An eastern cooperative oncology group study (E1404)

AU - Greenwald, Daniel R.

AU - Li, Hailun

AU - Luger, Selina M.

AU - Go, Ronald S.

AU - King, David

AU - Patel, Taral

AU - Gascoyne, Randy D.

AU - Kolesar, Jill

AU - Kahl, Brad S.

AU - Horning, Sandra

N1 - Funding Information: We would like to thank Dr. Ranjana Advani for her help in study implementation and review of the manuscript. This investigation was supported by Grant CA-23318, awarded by the National Cancer Institute, DHHS. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA15488, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2013

Y1 - 2013

N2 - Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

AB - Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

KW - Diffuse large B cell lymphoma

KW - MAP kinase signaling

KW - NHL

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84879805208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879805208&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-6-46

DO - 10.1186/1756-8722-6-46

M3 - Article

C2 - 23829878

AN - SCOPUS:84879805208

SN - 1756-8722

VL - 6

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 46

ER -

A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this